Nationwide Children’s Hospital and Ohio State University have operated a 5-day myology training course for the last seven years. The course includes common lectures in the mornings and separate clinical and laboratory tracks in the afternoons.
Recent announcements from three biotechnology and pharmaceutical companies reflect the increasing interest in and tractability of myotonic dystrophy for therapy development. Short summaries and links to the press releases are provided here.
Dr. Vincent Dion awarded $250,000 grant to pursue gene editing technology development to find a cure for DM.
The Myotonic Dystrophy Clinical Research Network (DMCRN) sites are currently conducting a critically-important research study designed to help drug developers successfully design clinical trials and understand how to assess the efficacy of potential therapies.
MDF designed this volunteer initiative to educate the next generation of medical professionals about myotonic dystrophy in order to improve clinical care and shorten the diagnostic odyssey. We need you!
Disorders of sleep and breathing are well characterized for DM1, but what about DM2?
A new review looks at the opportunities and hurdles for genome editing in neuromuscular disease.
Respiratory dysfunction in DM1 draws new attention.